125i nka

Manufactured by PerkinElmer

Sourced in United Kingdom, United States

[125I]-NKA is a radiolabeled peptide used for research purposes. It is a derivative of Neurokinin A, a neuropeptide involved in various physiological processes. [125I]-NKA is utilized as a tool in scientific investigations, but a detailed description of its core function cannot be provided while maintaining an unbiased and factual approach.

Automatically generated - may contain errors

Lab products found in correlation

2 protocols using 125i nka

Synthesis and Characterization of NKA Analogs

Check if the same lab product or an alternative is used in the 5 most similar protocols

NKA and the peptide analogs of NKA listed in Table 1 were synthesized by Genscript (Piscataway, USA) to a purity ≤95%. NKA and substance P were purchased from Sigma Aldrich, (St. Louis, USA); septide was purchased from Bachem (Bubendorf, Switzerland, EU). [³H]-Septide was custom synthesized from Quotient Bioresearch (Cardiff, UK). [¹²⁵I]-NKA, and Microscint 20, were obtained from Perkin Elmer (Boston, USA). F12K medium, Geneticin (G418) and Lipofectamine 2000 were obtained from LifeTechnologies (Carlsbad, USA). Phosphate buffered saline (PBS) was from Lonza (Walkersville, MD, USA) and EDTA from Life Technologies (New York, USA). FuGENE HD Transfection Reagent was obtained from Promega (Madison, USA). The following reagents were obtained from Sigma Aldrich (St. Louis, USA): DMSO, Pluronic F-127, HEPES, bacitracin, SIGMAFAST Protease Inhibitor Tablets, bovine serum albumin (BSA), polyethileneimine (PEI), NaCl, 3-isobutyl-1-methylxantine (IBMX), and probenecid. The CRE/CREB Reporter Assay Kit, Firefly Luciferase reagent, and Renilla Luciferase reagent were purchased from BPS Bioscience (San Diego, USA).

Rupniak N.M., Perdona E., Griffante C., Cavallini P., Sava A., Ricca D.J., Thor K.B., Burgard E.C, & Corsi M. (2018). Affinity, potency, efficacy, and selectivity of neurokinin A analogs at human recombinant NK2 and NK1 receptors. PLoS ONE, 13(10), e0205894.

+ Open protocol

+ Expand

Radioligand Binding Assay for NK2 and NK1 Receptors

Check if the same lab product or an alternative is used in the 5 most similar protocols

For displacement of radioligand binding to NK2 receptors, GR64349, NKA, or substance P were incubated with 0.1 nM [¹²⁵I]-NKA (specific activity 81.4 TBq/mmol; Perkin Elmer, Boston, USA) and membranes expressing NK2 receptors (6 μg/well) at 23°C for 3 h. Total binding to NK2 receptors was defined by addition of DMSO, and nonspecific binding by addition of 1 μM NKA. Experiments were performed in duplicate on 3 or 4 separate occasions. Competition for radioligand binding to NK1 receptors was examined by incubation of GR64349, NKA, or substance P with 5.0 nM [³H]-septide (specific activity 3.9 TBq/mmol; Quotient Bioresearch, Cardiff, UK) and membranes expressing NK1 receptors (20 μg/well) at 23°C for 1 h. Total binding to NK1 receptors was defined by addition of DMSO, and nonspecific binding was defined by addition of 1 μM septide. Experiments were performed in duplicate on 3 separate occasions.

Perdona E., Cavallini P., Sava A., Griffante C., Ricca D.J., Thor K.B., Rupniak N.M, & Corsi M. (2019). Potency, Efficacy, and Selectivity of GR64349 at Human Recombinant Neurokinin NK2 and NK1 Receptors. Neuroscience letters, 711, 134456.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!